FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 261 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR A tribute to Professor Gordon McVie February 18, 2021 Transforming Cancer Clinical Trials for Better, Faster Results April 14, 2023 Self-care Isn’t Selfish August 25, 2021 Is That New Lump or Bump a Sarcoma? February 28, 2023 Load more HOT NEWS Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus... Lack of Evidence for the Use of Telemedicine in the Prevention... Women Who Consume Cows’ Milk Increase Their Risk Of Breast Cancer... Lucky 13-A Male Breast Cancer Story
